芬戈莫德治疗对多发性硬化症患者循环miR-15b、miR-23a和miR-223水平的影响。
Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
作者信息
Fenoglio Chiara, De Riz Milena, Pietroboni Anna M, Calvi Alberto, Serpente Maria, Cioffi Sara M G, Arcaro Marina, Oldoni Emanuela, Scarpini Elio, Galimberti Daniela
机构信息
Dept. of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
出版信息
J Neuroimmunol. 2016 Oct 15;299:81-83. doi: 10.1016/j.jneuroim.2016.08.017. Epub 2016 Aug 31.
MicroRNAs (miRNAs) have recently found to be dysregulated in serum from multiple sclerosis (MS) patients. Cell free circulating miR-15b, -23a and 223 levels were analyzed by Real Time PCR in a cohort consisting of 30 serum samples from Relapsing Remitting MS patients at baseline (T0) and after three, six, nine and twelve months (T1, T2, T3, T4) after starting the treatment. A down-regulation of miRNA levels in patients at T0 compared with controls was present (p<0.001). MiRNA levels slightly increased at T1 and this trend reached the statistical significance at T2 vs T0 and remains stable at T3 and T4. Our preliminary results suggest that aberrant levels of circulating miRNAs are recovered in fingolimod treated MS patients. Circulating miRNAs profiling could thus represent an easy detectable biomarker of disease and response to treatment.
最近发现，微小RNA（miRNA）在多发性硬化症（MS）患者的血清中表达失调。通过实时聚合酶链反应（Real Time PCR）分析了30份复发缓解型MS患者血清样本中的游离循环miR-15b、-23a和223水平，这些样本分别来自基线期（T0）以及开始治疗后3个月、6个月、9个月和12个月（T1、T2、T3、T4）。与对照组相比，T0期患者的miRNA水平下调（p<0.001）。miRNA水平在T1期略有升高，这种趋势在T2期与T0期相比达到统计学意义，并在T3期和T4期保持稳定。我们的初步结果表明，在接受芬戈莫德治疗的MS患者中，循环miRNA的异常水平得到了恢复。因此，循环miRNA谱分析可能代表一种易于检测的疾病和治疗反应生物标志物。
Zotero 插件